株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

遺伝子検査の世界市場:産業分析、市場見通し

Global Genetic Testing Market - Segmented by Treatment Type, Diseases, Technology and Geography - Growth, Trends and Forecasts (2018 - 2023)

発行 Mordor Intelligence LLP 商品コード 319191
出版日 ページ情報 英文 120 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.48円で換算しております。
Back to Top
遺伝子検査の世界市場:産業分析、市場見通し Global Genetic Testing Market - Segmented by Treatment Type, Diseases, Technology and Geography - Growth, Trends and Forecasts (2018 - 2023)
出版日: 2018年02月08日 ページ情報: 英文 120 Pages
概要

当レポートでは、世界の遺伝子検査市場について調査分析を行い、市場概要、市場因子、セグメンテーション別考察、地域別分析、競合状況、主要企業のプロファイルなどについてまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 主な影響因子

第5章 市場概要と産業動向

  • 現在の市場シナリオ
  • ポーターのファイブフォース分析

第6章 市場の成長因子・成長阻害因子・機会・課題の分析

  • 市場発展因子
  • 市場発展阻害因子
  • 市場機会
  • 市場課題

第7章 遺伝子検査市場の分類

  • 種類別
  • 疾患別
  • 技術別
  • 地域別

第8章 競合情勢

  • M&A
  • 合意・競合・提携
  • 新製品の発売

第9章 企業プロファイル

第10章 アナリストによる投資機会の見通し

第11章 市場の将来見通し

目次
Product Code: 1905

Description

As of 2017, the global genetic testing market was valued at USD 9,367.0 million and is expected to record a CAGR of around 10.4% during 2018-2023 (the forecast period). In 2017, the North American genetic testing segment of the market studied accounted for the highest revenue and Asia-Pacific is expected to register the highest CAGR of 12.6% over the forecast period

Growing Demand for Personalized Medicine

Personalized medicine, where tailored therapy is made available to patients with an understanding of the molecular basis of diseases, has become popular over the recent years. Genetic testing and genome sequencing are two of the most important tools that are used to understand the molecular basis of a disease. European countries are screened for several genetic diseases, as an early detection of these diseases can prevent the onset of symptoms, or minimize the severity of the disease. Genetic testing for cancer diagnosis can indicate the predisposition of the disease in the gene, before its actual manifestation. This type of diagnostic technique enables a person to take precautionary steps, and avoid possible risks in the future.

Social and Ethical Implications of Genetic Testing

Insurance is an important asset to people. The fear of discrimination by insurance companies discourages people from undertaking genetic tests, which is a restraining factor for the market growth. The expensive nature of genetic tests affects the market, adversely. At times, the payments made by individuals are not reimbursed through insurance, thus, affecting the pockets of these patients. The high-import duty by the government on genetic tests kits also acts as a barrier to the market growth.

North America to Dominate the Market

The genetic testing market is segmented by treatment type, diseases, technology, and geography. By geography, the market has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.

Owing to the presence of well-established healthcare facilities and new discoveries in the field of genetic markers, North America dominates the genetic testing market. The Asia-Pacific market is expected to register the highest CAGR, as government and private firms are making significant investments in the healthcare industry. Over the last couple of years, to invest in the Japanese market, several mergers, acquisitions, and collaborations between companies have taken place.

Key Developments in the Market

September 2017: Myriad Launched riskScore to enhance the hereditary cancer test myRisk. riskScore determines the risk of women to get breast cancer by analyzing their genome.

July 2017: Admera Health Partners collaborates with Helix to Launch Genetic Tests to Assess the Risk of Inherited High Cholesterol, Sudden Cardiac Death, and Inherited Diabetes

Major Players: 23 AND ME INC., ABBOTT MOLECULAR INC, ARIOSA DIAGNOSTICS INC, BIOCARTIS SA, CEPHEID, ILLUMINA INC, LUMINEX CORPORATION, SEQUENOM INC, MYRIAD GENETICS, TRANSGENOMIC INC. amongst others.

Reasons to Purchase This Report

Market analysis for the Global Genetic testing Market, with region-specific assessments and competition analysis on the global and regional scale

Analyzing various market perspectives, with the help of Porter's five forces analysis

The treatment type that is expected to dominate the market

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares, and strategies employed by the major market players

3 months analyst support, along with the Market Estimate sheet (in excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threats of New Entrants
    • 5.2.4 Threat of Substitute Product And Services
    • 5.2.5 Competitive Rivalry Within the Industry

6. Drivers, Restraints, Opportunities And Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Increasing Emphasis on Early Disease Detection and Prevention
    • 6.1.2 Growing Demand for Personalized Medicine
    • 6.1.3 Increasing Application of Genetic Testing in Oncology
  • 6.2 Market Restraints
    • 6.2.1 High Costs of Genetic Testing
    • 6.2.2 Social and Ethical Implications of Genetic Testing
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 Segmentation-By Type
    • 7.1.1 Carrier Testing
    • 7.1.2 Diagnostic Testing
    • 7.1.3 Newborn Screening
    • 7.1.4 Predictive and Presymptomatic Testing
    • 7.1.5 Prenatal Testing
    • 7.1.6 Nutrigenomic Testing
  • 7.2 Segmentation-By Disease
    • 7.2.1 Alzheimer's Diseases
    • 7.2.2 Cancer
    • 7.2.3 Cystic Fibrosis
    • 7.2.4 Sickle Cell Anemia
    • 7.2.5 Duchenne Muscular Dystrophy
    • 7.2.6 Thalassemias
    • 7.2.7 Huntington's Disease
    • 7.2.8 Special Diseases
    • 7.2.9 Others
  • 7.3 Segmentation-By Technology
    • 7.3.1 Cytogenetic Testing
    • 7.3.2 Biochemical Testing
    • 7.3.3 Molecular Testing
  • 7.4 Segmentation-By Geography
    • 7.4.1 North America
      • 7.4.1.1 US
      • 7.4.1.2 Canada
      • 7.4.1.3 Mexico
    • 7.4.2 Europe
      • 7.4.2.1 France
      • 7.4.2.2 Germany
      • 7.4.2.3 UK
      • 7.4.2.4 Italy
      • 7.4.2.5 Spain
      • 7.4.2.6 Rest Of Europe (RoE)
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China
      • 7.4.3.2 Japan
      • 7.4.3.3 India
      • 7.4.3.4 Australia & New Zealand
      • 7.4.3.5 South Korea
      • 7.4.3.6 Rest Of Asia-Pacific
    • 7.4.4 Middle East & Africa
      • 7.4.4.1 GCC
      • 7.4.4.2 South Africa
      • 7.4.4.3 Rest Of the Middle East & Africa
    • 7.4.5 South America
      • 7.4.5.1 Brazil
      • 7.4.5.2 Argentina
      • 7.4.5.3 Rest Of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 23 and Me Inc.
  • 9.2 Abbott Molecular Inc.
  • 9.3 Ariosa Diagnostics Inc.
  • 9.4 Biocartis SA
  • 9.5 Cepheid
  • 9.6 Illumina Inc.
  • 9.7 Luminex Corporation
  • 9.8 Sequenom Inc.
  • 9.9 Myriad Genetics
  • 9.10 Transgenomic Inc.

10. Future of the Market

Back to Top